Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2024 16:25 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
November 27, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 25, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 12, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Open Letter to Shareholders

Open Letter to Shareholders
November 05, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
October 23, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
October 10, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
September 17, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
October 12, 2023 15:13 ET | Source: PrismHR

Marrying Form and Function, PrismHR Unveils New Unified Employee Experience (UEX)

PrismHR Unveils New Unified Employee Experience (UEX)
October 05, 2023 07:00 ET | Source: PrismHR

Kevin Andrews Named President of PrismHR

Kevin Andrews Named President of PrismHR

Next Page keyboard_arrow_right